ACADIA Pharma (ACAD): Price-to-Sales Ratio

Corporate company logo of ACADIA Pharmaceuticals Inc (ACAD)

Stable cash flow from neurological drug sales fully covers R&D investments, ensuring liquidity for ACADIA Pharmaceuticals (ACAD). This historical P/S chart reflects the business valuation dynamics relative to revenue, where the metric settled at 2.60. Efficiency gains are driven by AI-powered drug discovery automation, while niche market resilience is supported by in-house drug manufacturing in the US.

ACAD: ACADIA Pharmaceuticals P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for ACADIA Pharmaceuticals Inc (ACAD)

- share price and consensus valuation forecast:
Price Performance Chart acadia-pharm.com|ACAD - Price Target Chart
- stock exchange capitalization data:
Market Valuation ACADIA Pharmaceuticals Inc|ACAD - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share ACADIA Pharmaceuticals|ACAD - Book Capitalization|Market Capitalization to Book Value Ratio acadia-pharm.com|ACAD - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio ACADIA Corp|ACAD - Company Aggregate Debts|Debts to Book Capitalization ACADIA Pharmaceuticals Inc|ACAD - Company Long-Term Debts|Company Current Liabilities ACADIA Pharmaceuticals|Immediate Liquidity acadia-pharm.com
- earnings and valuation multiples information:
ACAD - Net Income|Projected Future Earnings ACADIA Pharmaceuticals|ACAD - Price to Earnings Ratio|Market Cap to Future Earnings Ratio ACADIA Pharma|ACAD - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio ACADIA Pharmaceuticals Inc|ACAD - Operating profit EBITDA|Net earnings per share for the last 12 months ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth acadia-pharm.com|ACAD - Earnings per share growth in current year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals
- issuer revenue and sales details:
ACAD - Company Revenue|Company Future Sales acadia-pharm.com|ACAD - P/S Multiple|Forward P/S Multiple ACADIA Pharmaceuticals Inc
General company analysis:ACAD acadia-pharm.com
Finished products of ACADIA Pharmaceuticals

The P/S ratio determines the market value of a business relative to its annual sales volume, allowing for an assessment of whether an asset is overpriced prior to the publication of financial statements. By analyzing the P/S level of ACADIA Pharmaceuticals (ACAD), an investor compares market capitalization with the distribution efficiency of neuropsychiatric drugs, where logistics optimization directly impacts revenue and justifies the current stock market value.

Competing companies

BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC (Regencell Bioscience Ltd) - Price-to-Sales Ratio|Axsome Therapeutics Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio XENE (Xenon Corp)|VKTX: P/S Multiple|supernus.com (SUPN) - P/S Multiple|Price-to-Revenue Ratio Catalyst Pharmaceuticals, Inc.|DNLI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Harmony Pharma (HRMY)|Market Cap to Revenue Biohaven Corp BHVN|P/S Multiple AMLX (Amylyx Pharmaceuticals)|P/S Multiple trevitherapeutics.com TRVI|Praxis Precision Medicines, Inc. - P/S Multiple|Anavex (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Price to Sales Prothena Corp (PRTA)|Market Cap to Revenue ALEC|P/S Multiple annexonbio.com|Market Cap to Revenue OMER (Omeros Corporation)|Market Cap to Sales Volume NGNE|P/S Multiple ACIU (AC Immune Corp)|Price-to-Revenue Coefficient Voyager Corp (VYGR)|Neumora Therapeutics - P/S Multiple|scilexholding.com (SCLX) - Market Cap to Revenue|TVGN: P/S Multiple|Alpha Cognition Inc. (ACOG) - P/S Multiple|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Price-to-Revenue Ratio IKT|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|Price-to-Revenue Coefficient assertiotx.com|P/S Multiple COYA (Coya Therapeutics)|P/S Multiple VistaGen Therapeutics, Inc. VTGN|Ovid Rx - P/S Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Revenue|CRVO: P/S Multiple|Alterity Therapeutics Limited (ATHE) - P/S Multiple|CLNN (Clene Inc) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen Corp)|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|Relmada Corp - Market Cap to Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Price to Sales|AIFF: Market Cap to Revenue|KLTO - P/S Multiple|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio MetaVia Inc.|Price to Sales neuraxis.com NRXS|P/S Multiple HSDT|P/S Multiple passagebio.com (PASG)|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV - Market Cap to Revenue|Athira Pharma, Inc. - P/S Multiple|ADXN - P/S Multiple|ALZN: P/S Multiple|Market Cap to Revenue Ratio CYCN|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Pasithea (KTTA) - Price-to-Revenue Coefficient|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|longboardpharma.com - Market Capitalization-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|P/S Multiple NKGen Biotech Inc|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN - Market Cap to Revenue|Vigil Neuro - P/S Multiple|WENA - P/S Multiple|CERE: P/S Multiple